» Articles » PMID: 21862698

Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial

Overview
Specialty Oncology
Date 2011 Aug 25
PMID 21862698
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

The double-blind, prospective, National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT) showed a 50% reduction in the risk of breast cancer for tamoxifen versus placebo, yet many women at risk of breast cancer do not adhere to the 5-year course. This first report of the rich BCPT drug adherence data examines predictors of adherence. Between June, 1992 and September, 1997 13,338 women at high risk of breast cancer were randomly assigned to 20 mg/d tamoxifen versus placebo; we analyzed the 11,064 enrolled more than 3 years before trial unblinding. Primary endpoint was full drug adherence (100% of assigned pills per staff report, excluding protocol-required discontinuation) at 1 and 36 months; secondary was adequate adherence (76%-100%). Protocol-specified multivariable logistic regression tested lifestyle factors, controlling for demographic and medical predictors. About 13% were current smokers; 60% were overweight/obese; 46% had moderate/heavy physical activity; 21%, 66%, 13% drank 0, 0-1, 1+ drinks per day, respectively; 91% were adequately adherent at 1 month; and 79% were at 3 years. Alcohol use was associated with reduced full adherence at 1 month (P = 0.016; OR = 0.79 1+ vs. 0), as was college education (P <0.001; OR = 0.78 vs. high school); age (P < 0.001; OR = 1.4 age 60+) and per capita household annual income (P < 0.001; OR = 1.2 per $30,000) with increased adherence. Current smoking (P = 0.003; OR = 0.75), age (P = 0.024, OR = 1.1), college education (P = 0.037; OR = 1.4), tamoxifen assignment (P = 0.031; OR = 0.84), and breast cancer risk (P <.001; OR = 1.5 high vs. low) predicted adequate adherence at 36 months. There were no significant associations with obesity or physical activity. Alcohol use and smoking might indicate a need for greater adherence support.

Citing Articles

Effect of neighborhood and individual-level socioeconomic factors on breast cancer screening adherence in a multi-ethnic study.

Kasper G, Momen M, Sorice K, Mayhand K, Handorf E, Gonzalez E BMC Public Health. 2024; 24(1):63.

PMID: 38166942 PMC: 10763410. DOI: 10.1186/s12889-023-17252-9.


Optimal breast cancer risk reduction policies tailored to personal risk level.

Ergun M, Hajjar A, Alagoz O, Rampurwala M Health Care Manag Sci. 2022; 25(3):363-388.

PMID: 35687269 PMC: 10445480. DOI: 10.1007/s10729-022-09596-2.


Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy.

Di Meglio A, Havas J, Gbenou A, Martin E, El-Mouhebb M, Pistilli B J Clin Oncol. 2022; 40(27):3190-3204.

PMID: 35446677 PMC: 9509127. DOI: 10.1200/JCO.21.00277.


Visualizing adverse events in clinical trials using correspondence analysis with R-package visae.

Diniz M, Gresham G, Kim S, Luu M, Henry N, Tighiouart M BMC Med Res Methodol. 2021; 21(1):244.

PMID: 34753452 PMC: 8579548. DOI: 10.1186/s12874-021-01368-w.


Characteristics of tobacco consumption among cancer patients at a tertiary cancer hospital in South India-A cross-sectional study.

Ramani V, V G, Benny N, Naik R Tob Use Insights. 2021; 14:1179173X211050395.

PMID: 34720601 PMC: 8554559. DOI: 10.1177/1179173X211050395.


References
1.
Costantino J, Gail M, Pee D, Anderson S, Redmond C, Benichou J . Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999; 91(18):1541-8. DOI: 10.1093/jnci/91.18.1541. View

2.
Murthy V, Bharia G, Sarin R . Tamoxifen non-compliance: does it matter?. Lancet Oncol. 2002; 3(11):654. DOI: 10.1016/s1470-2045(02)00895-1. View

3.
Fisher B, Costantino J, Wickerham D, Redmond C, Kavanah M, Cronin W . Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90(18):1371-88. DOI: 10.1093/jnci/90.18.1371. View

4.
Bober S, Hoke L, Duda R, Regan M, Tung N . Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol. 2004; 22(24):4951-7. DOI: 10.1200/JCO.2004.05.192. View

5.
Cella D, Land S, Chang C, Day R, Costantino J, Wolmark N . Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Res Treat. 2007; 109(3):515-26. DOI: 10.1007/s10549-007-9682-9. View